In the specialized field of molecular biology and immunology research, the MAGE A3 peptide has emerged as a cornerstone for those investigating the mechanisms of cellular recognition and antigen-specific responses. As a user deeply interested in the biochemical properties of synthetic peptides, I have spent considerable time reviewing how A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis these sequences are utilized Human MAGE-A3 Peptide Pool | T Cell Research | p&e in laboratory environments to study the MAGE family of proteins.
Understanding the MAGE A3 Entity
The Melanoma-associated antigen 3 (MAGE-A3) is a protein that in humans is encoded by the MAGEA3 gene. It belongs to the cancer testis family antigens, a group of proteins typically restricted to germ cells in healthy adult tissues but often expressed in various malignant cell lines. Because of this restricted expression pattern, MAGE-A3 is an attractive target for cancer therapy and diagnostic marker development.
When working with these materials, researchers often utilize a Human MAGE-A3 peptide pool. These pools are typically composed of overlapping 15-mer peptides, which are essential for comprehensive epitope mapping. One common product in this space is the MACS GMP PepTivator MAGE-A3, which is designed for efficient in vitro stimulation.
Technical Parameters and Research Applications
In my own review of high-quality materials, I have found that the MAGE-A3 (112-120) peptide (KVAELVHFL) serves as a critical reference point. It is a high quality epitope peptide frequently used in T-cell assays. Specifically, this peptide MAGE sequence is often studied for its ability to bind to HLA molecules, such as the HLA-A24 allele, which is vital for understanding how the immune system presents these markers.
Key technical aspects include:
* Synthetic Peptide Construction: High-purity synthetic peptide sequences are necessary to ensure consistency in immunological studies.
* Cytosolic Bioavailability: Recent advancements, such as MAGE-A3 with CPD enhances its cytosolic bioavailability in DCs (dendritic cells), have allowed for more nuanced studies regarding how these antigens are processed internally.
* Combinatorial Research: It is not uncommon to se MAGEA3 e studies involving MAGE-A3 and NY-ESO-1 peptide combinations, as these multi-antigen approaches provide a broader perspective on how cells react to multiple cancer-testis antigens simultaneously.
We developed novel, small-molecule ligands for MAGE-A3, a type I MAGE that is widely expressed in tumors and associates with TRIM28, a RING E3 ligase.Observations on Expression and Immunogenicity
The scientific literature consistently highlights that MAGEA3 expression in mRNA and protein were upregulated in LUAD (lung adenocarcinoma) and other tissues. This expression profile makes the study of human melanoma antigen A3 (MAGE-A3) crucial for those mapping the landscape of tumor-specific markers.
Furthermore, MAGEA3 demonstrated T-cell reactivity against highly conserved MAGE-A3 peptides in various preclinical setups. These findings are foundational for researchers aiming to understand the structural requirements for T-cell receptor (TCR) binding. It is fascinating to see how the specific amino acid sequences within the A Human MAGE-A3 peptide pool for T cell stimulation and epitope mapping. Professional quality for cancer-testis antigen (CTA) studies and immunotherapy. 3 protein structure influence the stabil Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy. ity of the peptide-MHC complex.
Conclusion for Researchers
For those of us involved in the procurement and analysis of these reagents, it is clear that MAGE-A3 is a cancer-testis antigen of immense significance. Whether you are working with a single peptide sequence for epitope binding or a full library for T-cell stimulation, the quality and purity of the MAGE A3 peptide are paramount. By focusing on these well-defined molecular structures, we continue to gain valuable insights into the complex interactions that define modern immunological research.
*Disclaimer: This article is for informational purposes for researchers and laboratory professionals. It does not constitute medical advice, and these produc by AD Martin · 2020 · Cited by 34 — In 2013, an innovative MAGE-A3-directed cancer therapeutic of great potential value was terminated in the clinic because of neurotoxicity. ts are not for human use.*